Published on: August 5, 2015
by Psychiatry Advisor:
Medications commonly used to treat dementia could result in harmful weight loss, according to University of California, San Francisco researchers, and clinicians need to account for this risk when prescribing these drugs to older adults, they said.
Alzheimer’s disease and other dementias are prevalent, affecting one in six people over age 80. The main drug treatments, a class of medications called cholinesterase inhibitors (i.e., donepezil, galantamine, rivastigmine), are marginally beneficial for most patients and may have serious side effects such as gastrointestinal symptoms.
Weight loss also is a significant problem in dementia patients and linked to increased mortality. Data from randomized controlled trials suggests this weight loss may be an under-recognized side effect of cholinesterase inhibitors, but evidence is limited and conflicting.
the Psychiatry Advisor take:
Cholinesterase inhibitors, a class of medication commonly used in the treatment of dementia, may lead to extreme weight loss in some instances.
Drugs in this category include donepezil (Aricept), galantamine (Razadyne) and rivastigmine (Exelon).
Meera Sheffrin, MD, geriatrics fellow in the University of California, San Francisco School of Medicine and with the San Francisco VA Medical Center, examined national VA data from 2007-2010 to evaluate patients 65 and older diagnosed with dementia who received a new prescription for a cholinesterase inhibitor or other new chronic medication.
A total of 1,188 patients started on cholinesterase inhibitors were matched to 2,189 patients started on other medications. At 12 months, 78% were still on the inhibitors, compared to 66% for other medications. And, about 29.3% of patients on the inhibitors experienced significant weight loss, compared to 22.8% of non-users, the researchers reported in Journal of the American Geriatrics Society.
The results indicate that patients started on the cholinesterase inhibitors had a higher risk of clinically significant weight loss over a 12-month period compared to control. Put another way, one out of every 21 patients treated experienced at least a 10-pound weight loss.
“This is very relevant to patient care because unintentional weight loss in older adults is associated with many adverse outcomes, including increased rates of institutionalization and mortality, a decline in functional status, and poorer quality of life,” Sheffrin said in a statement.
Thanks to the ongoing support of our partner Brain Canada, and The Citrine Foundation of Canada, Women’s Brain Health Initiative’s newest edition of MIND OVER MATTER has just been published. Loaded with interesting science-based articles, MIND OVER...
On December 2nd, in celebration of Women’s Brain Health Day, join thousands of others and take part in the Stand Ahead® Memory Challenge to stand up against research bias and stand ahead for women’s brain...
YOU’RE INVITED! On December 2nd, the second annual Women’s Brain Health Day, take the memory challenge and help us combat brain-aging diseases that disproportionately affect women. Join CTV’s Pattie Lovett-Reid and Anne-Marie Mediwake, along...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.